Neuropeptide Y/Agouti-related protein (NPY/AgRP) neurons are a population of orexigenic (appetite-stimulating) neurons located primarily in the arcuate nucleus (ARC) of the hypothalamus. These neurons are the most potent known drivers of food intake and regulate energy homeostasis through secretion of NPY and AgRP, which act on Y receptor subtypes (Y1, Y2, Y4, Y5) throughout the brain. AgRP acts as an inverse agonist at melanocortin-3 and melanocortin-4 receptors, blocking the appetite-suppressing effects of α-melanocyte-stimulating hormone (α-MSH) from POMC neurons.
NPY/AgRP neurons are GABAergic and receive inputs from leptin-expressing adipocytes (via the arcuate nucleus), insulin-signaling neurons, ghrelin-secreting stomach cells, and higher-order forebrain regions including the prefrontal cortex. They project to the lateral hypothalamus, paraventricular nucleus, and brainstem regions involved in autonomic and behavioral control of feeding.
| Peptide | Gene | Function | Receptors |
|---|---|---|---|
| NPY | NPY | Potent appetite stimulator | Y1, Y2, Y4, Y5 |
| AgRP | AGRP | Inverse melanocortin agonist | MC3R, MC4R |
| GABA | — | Inhibitory neurotransmitter | GABA-A, GABA-B |
| NPY Y1R | NPY1R | Autocrine/paracrine signaling | — |
NPY/AgRP neurons exhibit distinctive electrophysiological properties:
The primary population resides in the arcuate nucleus of the hypothalamus. A smaller scattered population exists in the lateral hypothalamus and adjacent regions. NPY terminals are found throughout the forebrain, with particularly high density in the paraventricular hypothalamus, dorsomedial hypothalamus, and perifornical area.
Alzheimer's disease patients frequently develop metabolic disturbances including weight loss, anorexia, and dysregulated energy homeostasis — features that correlate with disease severity and can precede cognitive decline. NPY/AgRP neurons contribute to these phenotypes through several mechanisms:
Parkinson's disease is associated with significant metabolic changes including weight loss, cachexia, and gastrointestinal dysfunction. NPY/AgRP neurons are implicated in these non-motor features:
ALS patients commonly experience hypermetabolism and weight loss. NPY/AgRP neuron activity may contribute to the metabolic component, particularly in bulbar-onset ALS where feeding circuits are directly affected.
Targeting NPY/AgRP neurons or their receptors represents a therapeutic strategy for metabolic dysfunction in neurodegeneration:
| Target | Approach | Disease | Rationale |
|---|---|---|---|
| Y2 receptor | Antagonists | AD | Reduce orexigenic drive, improve metabolic balance |
| MC4R | Agonists | AD/PD | Counteract AgRP inverse agonism |
| Ghrelin/GHSR axis | Modulators | PD | Normalize hunger signaling |
| Hypothalamic inflammation | Anti-IL-1β | AD/PD | Restore metabolic circuit function |
| Partner | Interaction | Role |
|---|---|---|
| POMC neurons | Mutual inhibition | Melanocortin axis homeostasis |
| Leptin | Leptin receptor signaling | Fed state suppression |
| Insulin | Insulin receptor signaling | Metabolic integration |
| Ghrelin | GHSR1a activation | Fasting state activation |
| Neuroinflammation | Cytokine modulation | Metabolic dysregulation |